Index to Volume 5, 1986
(No. 1 pp 1–62; No. 2 pp 63–140, No. 3 pp 141–202; No. 4 pp 203–260)

Abdominal pain
  caused by quinine, 217
    mercury, 156
Abortion
  caused by quinine, 219–220
Adjuvants, immunological
  bacterial, 14
  exogenous, 5–8
  mineral, 14–15
Adverse reactions
  caused by anticonvulsants, 63–77
    benzodiazepines, 76
    carbamazepine, 74
    clonazepam, 76
    ethosuximide, 75
    mercury, 142–143, 156–162
    phenobarbitone, 74
    phenytoin, 74–75
    primidone, 75
    sodium valproate, 75
  national differences, 47–51
  reporting, 23–54
  reporting rates, 25–26
    effect of prescribing habits, 31–33
      regulation, 33–36
      religion, 33–36
  reporting systems, 23–54
    international comparisons, 23–33
    Italy, 25
    Japan, 25
    New Zealand, 25
    West Germany, 24–25
  reports
    media bias, 46–47
    monitoring bias, 47
    source, 27–30, 31–33
    voluntary systems, 23–54
Agranulocytosis—*see* Blood disorders
'Allergic' reactions
  caused by quinine, 218
Aluminium salts
  as immunological adjuvants, 14–15
Anaemia—*see* Blood disorders
Antiarrhythmic drugs
  causing cardiac arrhythmias, 203–213
Anticonvulsants
  adverse effects, 63–77
    genetic predisposition, 64–65
    mechanisms, 64–65
    on blood, 69
    central nervous system, 65–66
    connective tissue, 67–68
    endocrine system, 69–70
    gastrointestinal system, 68
    haemopoiesis, 69
    liver, 68
    muscle, 67
    peripheral nerves, 67
    skin, 68
    skeletal system, 67
    thyroid function, 69–70
    vitamin D metabolism, 67
  pathological factors, 65
    physiological factors, 65
  causing effect on hormone metabolism, 66
    monoamine metabolism, 66
    exaggerated therapeutic response, 64
    folate deficiency, 66
    gingival hyperplasia, 67–68
    IgA deficiency
    myasthenic syndrome, 67
    osteomalacia, 67
    teratogenic effects, 70–71
Antiviral activity
  of glycoprotein, 6
    interferons, 6
    proteins, 6
Antiviral agents, 6
Ataxia
  caused by quinine, 221

Bacterial cells
  as immunological adjuvants, 14
B cells
  and the immune response, 2–3
BCG
  adverse effects, 11–13
  anti-tumour effects, 10
Benzodiazepines
  adverse effects, 76
Blackwater fever
  caused by quinine, 219
Blindness
  caused by quinine, 218
Blood disorders
  caused by
    anticonvulsants, 69
    chloramphenicol, 181–194
    doxorubicin, 100
    mercury, 160
    methotrexate, 100
    mianserin, 105–112, 192–193
    nitrogen mustard, 100
    oxyphenbutazone, 114, 120–124, 192–193
    phenylbutazone, 112–120, 123–124, 192–193

quinine, 218–219
vinca alkaloids, 100
genetic predisposition, 101–102
Bone marrow depression—*see* Blood disorders
Book reviews, 57–62, 137–140, 197–202, 257–260
Breast milk
mercury in, 149

Carbamazepine
adverse effects, 74
Calcium salts
as immunological adjuvants, 14–15
Cardiac arrhythmias
caused by
antiarrhythmic drugs, 203–213
mercury, 157
clinical implications, 209–212
diagnosis, 204–208
electrophysiology, 208
plasma drug levels, 208–209
Cardiotoxicity
caused by quinine, 217, 223
Cellular response
role of lymphocytes, 2
reticuloendothelial cells, 2
Chloramphenicol
causing blood disorders, 181–194
Cinchonism
caused by quinine, 217
Clonazepam—*see* Anticonvulsants
Coma
caused by quinine, 221
Connective tissue disorders
caused by anticonvulsants, 67–68
Convulsions
caused by quinine, 221
Corynebacterium parvum
anti-tumour effect, 10
as immunological adjuvant, 13

Data quality
in post-marketing surveillance, 87–94
Deafness
caused by quinine, 218
Diarrhoea
caused by quinine, 217
Digoxin
interaction with quinine, 223
quinidine, 223
Diuretics, mercurial
action, 151
history, 141
toxicity, 151

DNA synthesis
effects of oxyphenbutazone, 124–126
phenylbutazone, 124–126
Doxorubicin
causing blood disorders, 100
Drug interactions
digoxin—quinine, 223
Drug reactions—*see* Adverse reactions
Dysphagia
caused by mercury, 156

Endocrine disorders
caused by anticonvulsants, 69–70
Erythema multiforme
caused by quinine, 221
Ethosuximide—*see* Anticonvulsants
Eye damage
caused by quinine, 218, 221–223

Fetal damage
caused by mercury, 160–161
quinine, 221
Fixed drug eruption
caused by quinine, 221
Folate deficiency
caused by phenobarbitone, 66
phenytoin, 66

Gastrointestinal disorders
caused by anticonvulsants, 68
quinine, 217
Genetic toxicology
genotoxins, 238–240
history, 236–238
legislative requirements, 246
monitoring, 247–249
mutagenesis
in man, 238–239
in mice, 239
risk assessment, 249
tests, 240–245
cell transformation, 244–245
chromosome effects, 242–244
DNA interaction, 244
gene mutation, 241–242
validation studies, 245–246
Gingival hyperplasia
caused by anticonvulsants, 67–68
Gingivitis
caused by mercury, 156
Glycoproteins
antiviral activity, 6

Haemopoietic disorders—*see* Blood disorders
Hepatitis
  caused by quinine, 219
Hormone metabolism
  effect of anticonvulsants, 66
Hypoglycaemia
  caused by quinine, 221

IgA deficiency
  caused by anticonvulsants, 67
Immune response, 1–3
  and B cells, 2–3
    lymphocytes, 1, 2–3
    reticuloendothelial cells, 1
  classification, 1–2
  induction, 3
  modulation, 3
Immunological adjuvants, 8–10
  adverse effects, 1–16
  classification, 4
  effect on antibodies, 3–8
  endogenous, 5
  exogenous, 8–10
  in vaccines, 5
Interferons
  adverse effects, 7–8
  as antiviral agents, 6
  as endogenous adjuvants, 5–6
  causing pyrexia, 8
    skin reactions, 8
  classification, 6
  inducers, 8–10
    adverse effects, 9–10
  production, 6

Killer cells, 2

Leukaemia—*see* Blood disorders
Liver disorders
  caused by anticonvulsants, 68
    mercury, 157
Lung disorders
  caused by mercury, 156
Lymphocytes
  and immune response, 1
Lymphokines, 5–6

Marrow dyplasia–*see* Blood disorders
Melaena
  caused by mercury, 156
Mercurial diuretics—*see* Diuretics, Mercurial
Mercury, organic
  absorption
    gastrointestinal, 148
    lung, 148
    skin, 148
    vaginal, 159
  biotransformation, 149–150
  causing
    abdominal pain, 156
    blood disorders, 160
    cardiac arrhythmias, 157
    dysphagia, 156
    fetal damage, 160–161
    gingivitis, 156
    liver disorders, 157
    lung disorders, 156
    melaena, 156
    nasopharyngeal irritation, 156
    nausea, 156
    neurological disorders, 143, 160
    renal damage, 157
    skin disorders, 157–158
    stomatitis, 156
    taste disorders, 156
    vomiting, 156
  chemical forms, 144
  distribution, bodily, 148–149
  excretion, 150
  history, 141
  in breast milk, 149
    gamma-globulin injection, 159
    opthalmic preservatives, 158–159
  metabolic effects, 156
  methods of detection and analysis, 144–147
  mutagenicity, 153–154, 161
  occupational exposure, 162
  pharmacokinetics, 147–151
  pharmacology, 147–151
  placental transfer, 149
  poisoning
    acute, 142–143
    chronic, 143
    occupational, 162–172
    epidemiology, 165–168
    prevention, 168–172
    treatment, 162–165
  sources of exposure, 143–144
  teratogenicity, 154–155, 162
  toxicity, 141–172
Methotrexate
  causing blood disorders, 100
Mianserin
  causing blood disorders, 105–112, 192–194
Mineral adjuvants, 14–15
Microbiological adjuvants, 10–14
Monoamine metabolism
  effects of anticonvulsants, 66

Muramyl dipeptide
as immunological adjuvant, 14
Musculoskeletal disorders
caused by anticonvulsants, 67
quinidine, 221
quinine, 220–221
Mutagenicity, 126–128, 238–239
of oxyphenbutazone, 126–128
phenylbutazone, 126–128
Myasthenia
aggravated by quinine, 220
caused by anticonvulsants, 67
Mycobacteria
adverse effects, 11–12
Myelo-optico-neuropathy
caused by quinine, 221
Myelotoxicity—*see* Blood disorders
Myocardial depression
caused by quinine, 217, 223

Nasopharyngeal irritation
caused by mercury, 156
Nausea
caused by mercury, 156
Neurological disorders
caused by anticonvulsants, 66–67
mercury, 143, 160
Nitrogen mustard
causing blood disorders, 100

Ocular damage
caused by quinine, 218, 221–223
Osteomalacia
caused by anticonvulsants, 67
Ototoxicity
caused by quinine, 218
Oxyphenbutazone
causing blood disorders, 114, 120–124, 192–193
effect on DNA synthesis, 124–126
mutagenicity, 126–128

Peripheral nerve damage
caused by anticonvulsants, 67
Phenobarbitone
adverse effects, 74
causing folate deficiency, 66
Phenylbutazone
causing blood disorders, 112–120, 123–124, 192–193
effects on DNA synthesis, 124–126
mutagenicity, 126–128
Phenytoin
adverse effects, 74–75
causing folate deficiency, 66
Placental transfer
of mercury, 149
Primidone
adverse effects, 75
Post-marketing surveillance
data quality, 87–94
Prescribing habits
and adverse reaction reporting, 31–33
Proteins
antiviral activity, 6

Quinine
causing abdominal pain, 217
abortion, 219–220
'allergic' reactions, 218
ataxia, 221
blackwater fever, 219
blindness, 218
blood disorders, 218–219
cardiac depression, 216–217, 223
cardiotoxicity, 217, 223
cinchonism, 217
coma, 221
convulsions, 221
deafness, 218
diarrhoea, 217
erythema multiforme, 221
eye damage, 218, 221–223
fetal damage, 220
fixed drug eruption, 221
gastrointestinal disorders, 217
hepatitis, 219
hypoglycaemia, 221
myasthenia, aggravation, 220
myelo-optico-neuropathy, 221
myocardial depression, 217, 223
ocular damage, 218, 221–223
ototoxicity, 218
respiratory depression, 221
skin disorders, 221
tinnitus, 218
vasomotor disorders, 217
visual field defects, 218
vomiting, 217
interaction with digoxin, 223
pharmacology, 216
poisoning, 223–229
treatment, 224–229

Respiratory depression
caused by quinine, 221

Reticuloendothelial cells
and immune response, 1

Skeletal disorders
caused by anticonvulsants, 67
Skin disorders
caused by anticonvulsants, 67–68
mercury, 157–158
quinine, 221
Sodium Valproate
adverse effects, 75
Stomatitis
caused by mercury, 156

Taste disorders
caused by mercury, 156
Teratogenic effects
caused by anticonvulsant therapy, 70–71
Thrombocytopenia—*see* Blood disorders
Thyroid disorders
caused by anticonvulsants, 69–70
Tinnitus
caused by quinine, 218
T-lymphocytes
in cellular response, 2–3

Vasomotor disorders
caused by quinine, 217
Vinca alkaloids
causing blood disorders, 100
Visual field defects
caused by quinine, 218
Vit D metabolism
effects of anticonvulsants, 67
Vomiting
caused by mercury, 156
quinine, 217

Wax D
as immunological adjuvant, 14
World Health Organisation
drug monitoring activities, 36–47

Yellow-card adverse reaction reporting
system, 98

Contents of Volume 5 1986

Spring 1986

Immunological adjuvants of natural origin and their adverse effects

Voluntary systems of adverse reaction reporting—Part II

Book reviews

Summer 1986

Adverse effects of anticonvulsant drugs—a a critical review

Data quality in post-marketing surveillance

Bone marrow depression due to mianserin, phenylbutazone, oxygenbutazone, and chloramphenicol—Part I

Book reviews

Autumn 1986

Organic mercury compounds and their toxicity

Bone marrow depression due to mianserin, phenylbutazone, oxygenbutazone, and chloramphenicol—Part II

Book reviews

Winter 1986

Arrhythmogenic effects of antiarrhythmic drugs

Quinine toxicity

Genetic toxicology: a review

Book reviews